Dr. Illana Gozes is a Professor of Clinical Biochemistry, the Lily and Avraham Gildor Chair for the Investigation of Growth factors at Tel Aviv University, where she directs the Adams Super Center for Brain Studies, the Levie-Edersheim-Gitter Institute for Functional Brain Imaging. At the Sackler Faculty of Medicine, Professor Gozes heads the Dr. Diana and Zelman Elton (Elbaum) Laboratory for Molecular Neuroendocrinology (including ~15 staff members). Professor Gozes currently serves as a member of Tel Aviv University Governing Committee. Professor Gozes is the Editor-in Chief of the Journal of Molecular Neuroscience and is serving or has served as a member (or chair) of several faculty/university/national and international committees. For example, Professor Gozes heads the Tel Aviv Chapter of the Society for Neuroscience, serves as a member of the Israel Brain and the Israel Alzheimer’s and Dementia Association Councils, is an Associate Editor on the Journal of Alzheimer’s Disease and is an Ex-President of the Israel Society for Neuroscience (ISFN). In addition, Professor Gozes is involved in the organization of many high-profile scientific meetings worldwide and is serving as the Chair of the Summer Neuropeptide Conference, the secretary general of the European Neuropeptide Club and a member of the Board of the European Society for Neurochemistry. Professor Gozes was the Founding Scientist and a Director at Allon Therapeutics Inc., Vancouver, Canada.

Dr Gozes received her BSc from Tel Aviv University, her PhD from the Feinberg Graduate School at the Weizmann Institute of Science in Israel and was a postdoctoral fellow at Massachusetts Institute of Technology (MIT), USA. She was also a research associate and a visiting scientist at the Salk Institute and the Scripps Clinic and Research Foundation (USA) a Senior Scientist/Associate Professor at the Weizmann Institute of Science and a Fogarty Scholar – in – Residence at the National Institutes of Health (NIH, USA). Prof. Gozes has published ~300 papers, in the fields of molecular neuroscience, neuropeptides and neuroprotection. There are ~70 results (encompassing >15 patent families) found in the worldwide database for Gozes as an inventor, including the composition of matter patent on davunetide a clinical Phase 2-3 drug candidate (originally developed by Allon Therapeutics Inc. Professor Gozes won many awards of excellence (among them, the Tel Aviv University Vice President Award for Innovative Research, Olson Prize for the most meritorious original research article in Peptides, the Julodan Prize, the Teva Founders Prize, the Neufeld Research Award, the Humboldt Research Award, and the Landau Prize for Life Achievements, 2013).

Share The Story